Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Advisory Committees Biosimilars Regulation

Edging Toward Interchangeability in Biosimilars

  • Opinion

Executive Summary

An impressive performance by Sandoz at the July 13 Arthritis Advisory Committee on its etanercept biosimilar application suggests progress on the learning curve towards interchangeable applications.

You may also be interested in...



Sandoz's Multi-Switch Biosimilar Trials: A View To Interchangeability?

Company's application development seems to be outpacing FDA's policy development in next step along the 351(k) pathway.

Sandoz's Multi-Switch Biosimilar Trials: A View To Interchangeability?

Company's application development seems to be outpacing FDA's policy development in next step along the 351(k) pathway.

Biosimilars' Pediatric Pressures Could Push Them Toward Interchangeability

Study and formulation requirements under PREA mean that interchangeability application might not be much more of a leap.

Table

View full table

Related Content

Pink Sheet

Topics

Related Companies

Tags:
Advisory Committees Biosimilars Regulation
Latest Headlines

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116

Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length

German HTA Queries Polivy Benefits Amid Lack Of Evidence

See All
UsernamePublicRestriction

Register

PS118805

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By